Key Highlights
● Dyne reported that hand-opening time improved by 3.2 seconds at six months in the pooled group, while placebo worsened.
● The registrational cohort, ACHIEVE REC, is fully enrolled with 71 participants, and topline data are due in early 2027.
● Dyne plans a Biologics License Application in the third quarter of 2027; the filing reports no FDA determination.
● Only 8 of the 26 pooled participants received the registrational dose for the full 12 months, the company says.
Dyne Therapeutics, Inc. (NASDAQ:DYN) filed a Form 8-K on September 29, 2026, reporting under Items 7.01 and 8.01 additional one-year data from ACHIEVE, its Phase 1/2 clinical trial of z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1). The company said hand-opening time improved by 3.2 seconds at six months, that topline data from the registrational expansion cohort are expected in the first quarter of 2027, and that a Biologics License Application (BLA) submission under the U.S. Accelerated Approval pathway is planned for the third quarter of 2027. Two exhibits, a press release and a presentation, accompany the filing.
The ACHIEVE Results
The press release reports on a pooled dose group of about 25 to 26 participants, compared with a placebo group of 14 and matched natural history cohorts of 41 to 46 people, depending on the measure. On video hand opening time (vHOT), a timed hand-opening test, the pooled group started at a baseline of 8.2 seconds and improved by 3.2 seconds at six months, while the placebo group worsened by 0.4 seconds, a relative difference of 3.6 seconds.
At 12 months, the company reports a 4.8 percent-of-predicted improvement in muscle strength as measured by total quantitative muscle testing and hand grip, with divergence from the natural history cohort on both measures. It reports a 1.2-second improvement in the five-times sit-to-stand test and a 0.3-second improvement in the 10-meter walk/run test, with divergence from natural history on the latter. On patient-reported outcomes, the total score on the Myotonic Dystrophy Health index improved by 25.2 percent at 12 months. The material does not provide p-values for these results.
Safety and the Caveats the Company States
The press release says z-basivarsen continued to demonstrate a favorable safety profile and that no related serious treatment-emergent adverse events were identified.
The company is explicit about the limits of the data. The pooled dose group includes participants with mixed dose exposures and does not reflect the registrational dose, 6.8 mg/kg given every eight weeks, maintained for the full 12 months. Only 8 of the 26 participants received the registrational dose for the entire 12-month period. The five-times sit-to-stand test was not part of the natural history study, so no comparison is available for it.
The Registrational Expansion Cohort
The registrational expansion cohort, called ACHIEVE REC, is fully enrolled with 71 participants. Its mean baseline vHOT was 8.3 seconds, with a Standard Deviation of 6.0, and baseline data remain blinded to treatment assignment. The primary endpoint is the change from baseline in vHOT at six months. Topline data are expected in the first quarter of 2027.
The filing states that the company plans to submit a BLA in the third quarter of 2027 and to seek accelerated approval. The plan is the company's own; the filing does not report any determination by the U.S. Food and Drug Administration.
Chief Medical Officer Doug Kerr, M.D., Ph.D., is quoted as saying the company is presenting data at six and 12 months from a larger pooled dose group. The data are being shown this week at two scientific meetings: the World Muscle Society congress, running September 29 to October 3, 2026, in Hiroshima, Japan and virtually, and the AANEM meeting, running September 29 to October 2, 2026, in Orlando, Florida and virtually.
ACHIEVE REC Readout Ahead of Dyne's 2027 BLA
The first dated marker is the topline readout from ACHIEVE REC in the first quarter of 2027, which will show whether the six-month vHOT result seen in the pooled group is reproduced in the registrational cohort. A BLA submission is planned for the third quarter of 2027, and whether the FDA accepts it, and on what basis, will follow from the agency's review.






Please wait processing your request...